Fig. 11
Tumoral c-Jun expression level predicts the efficacy of chemotherapy and irbesartan plus chemotherapy regimens in human PDAC patients. A-C PDAC patients in Cohort1# received post-operative chemotherapeutic regimen of gemcitabine/nab-paclitaxel. Representative CT-scanning images of the two patients were shown (A), representative IHC staining of c-Jun from the two patients were shown (B) and the association of c-Jun expression with RFS rate in PDAC patients were analysed (C). Red arrows marked the metastases. L, liver; T, tumour. D-G Advanced PDAC patients in Cohort2# received GEM/nab-paclitaxel chemotherapy. Representative CT-scanning images of the responder and non-responder were shown (D), representative IHC staining of c-Jun from the pancreas needle biopsy tissues were shown (E), Kaplan–Meier OS for different levels of c-Jun of advanced PDAC patients based on the log-rank statistic test (F). Red arrows marked the metastases. Red dash lines indicated the pancreatic tumours. L, liver; T, tumour. Chemotherapy response data of all advanced patients in Cohort2# were collected and the relationship between chemotherapy response and tissue c-Jun expression level were analyzed by Chi-Square T test (G). PR, partial remission; SD, stable disease; PD, progressed disease. H Flowchart of patients enrolling in Cohort3# and Cohort4#. I-J Kaplan–Meier OS for advanced PDAC patients receiving GEM/nab-paclitaxel and irbesartan plus GEM/nab-paclitaxel regimen based on the log-rank statistic test in Cohort3# (I) and Cohort4# (J). K Representative CT-scanning images of the responder and non-responder for irbesartan plus GEM/nab-paclitaxel regimen in Cohort3# were shown. Red arrows marked the metastases. Red dash lines indicated the pancreatic tumours. L, liver or lung; T, tumour. L-MThe change in tumor diameter for PDAC patients with irbesartan plus GEM/nab-paclitaxel therapy in Cohort 3# and Cohort4#, those with increased tumor diameter were colored by red (L, left; M, left). Quantitative correlation between the change in tumor diameter and tumoral c-Jun expression levels based on Spearman’s rank correlation test (L, right; M, right)